Geode Capital Management LLC Has $227.04 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Geode Capital Management LLC increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,233,211 shares of the medical research company’s stock after acquiring an additional 14,787 shares during the quarter. Geode Capital Management LLC owned 2.41% of Charles River Laboratories International worth $227,042,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of Charles River Laboratories International during the third quarter valued at about $601,000. JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares during the period. State Street Corp boosted its holdings in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the third quarter valued at approximately $966,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the company from $190.00 to $170.00 in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $136.95 on Friday. The company has a market capitalization of $7.00 billion, a P/E ratio of 912.99, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company’s 50-day moving average is $162.49 and its 200 day moving average is $180.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $132.99 and a fifty-two week high of $258.56.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the previous year, the company earned $2.46 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).